Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer ... DailyFinance ... monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab ... Roche antibody tops Rituxan in blood cancer CLL Genentech Trumpets Phase III Results for CLL Candidate |
